The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20161686: Wells Fargo & Company; Harindra de Silva
20161710: ValueAct Capital Master Fund, L.P.; Seagate Technology plc
20161730: Paine & Partners Capital Fund IV, L.P.; Inverness Graham Investments II, L.P.
20161734: Boral Limited; Bricks Holdings LLC
20161735: LSF9 Stardust Holdings, LP; Bricks Holdings LLC
20161736: The Southern Company; Calpine Corporation
20161738: Roark Capital Partners IV AIV I-U, LP; James John Liautaud
20161741: EOG Resources, Inc.; Yates Petroleum Corporation
20161746: Pioneer Super Holdings, Inc.; Spectrum Tracer Services, LLC
1609005 Informal Interpretation
20161638: Aristeia International Limited; Yahoo! Inc.
20161705: Post Holdings, Inc.; National Pasteurized Eggs, Inc.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Teva and Allergan, In the Matter of
Teva Pharmaceutical Industries Ltd. agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges that its proposed $40.5 billion acquisition of Allergan plc’s generic pharmaceutical business would be anticompetitive. The remedy requires Teva to divest the drug portfolio to eleven firms, and will preserve competition in U.S. pharmaceutical markets where Teva and Allergan compete now or would likely have competed in the future if not for the merger. The divested products include anesthetics, antibiotics, weight loss drugs, oral contraceptives, and treatments for a wide variety of diseases and conditions, including ADHD, allergies, arthritis, cancers, diabetes, high blood pressure, high cholesterol, mental illnesses, opioid dependence, pain, Parkinson’s disease, and respiratory, skin and sleep disorders. The acquirers of the divested products are Mayne Pharma Group Ltd., Impax Laboratories, Inc., Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited, Zydus Worldwide DMCC, Mikah Pharma LLC, Perrigo Pharma International D.A.C., Aurobindo Pharma USA, Inc., Prasco LLC and 3M Company. In addition to the product divestitures, to address the anticompetitive effects likely to arise in markets for 15 pharmaceutical products where Teva supplies active pharmaceutical ingredients to current or future Allergan competitors, the FTC order additionally requires Teva to offer these existing API customers the option of entering into long-term API supply contracts.